Bone imaging in prostate cancer

Nature Clinical Practice Urology

Volumn 5, Issue 8, 2008, Pages 434-444

  Dotan, Zohar A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CAPROMAB PENDETIDE IN 111; CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

BONE EXAMINATION; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; HUMAN; HYPERCALCEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD COMPRESSION;

BONE AND BONES; BONE NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 49249106857     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1190     Document Type: Review

References (73)

1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 15: 1588-1594
2. Berenson JR et al. (2006) Pathophysiology of bone metastases. Cancer Biol Ther 5: 1078-1081
3. Jemal A et al. (2007) Cancer statistics 2007. CA Cancer J Clin 57: 43-66
4. Mundy GR (2002) Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593
5. Reikerås O et al. (1988) Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity. Int Urol Nephrol 20: 51-54
6. Rosenthal DI (1997) Radiologic diagnosis of bone metastases. Cancer 15: 1595-1607
7. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1656
8. Raubenheimer EJ et al. (2006) Pathogenesis of bone metastasis. J Oral Pathol Med 35: 129-135
9. Keller ET et al. (2001) Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 20: 333-349
10. Selvaggi G et al. (2005) Management of bone metastases in cancer a review. Crit Rev Oncol Hematol 56: 365-378
11. Scott LJ et al. (2001) Interactions of human prostatic epithelial cells with bone marrow endothelium: Binding and invasion. Br J Cancer 84: 1417-1423
12. Choueiri MB et al (2006) The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25: 601-609
13. Lehr JE and Pienta KJ (1998) Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90: 118-123
14. 99mTc-labeled polyphosphate as a skeletal imaging agent. Radiology 102: 701-704
15. 99mTc-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases. Am J Roentgenol 125: 972-977
16. VDMSA scintigraphy in skeletal metastases and superscans arising from various malignancies: Diagnosis, treatment monitoring and therapeutic implications. Br J Radiol 77: 347-361
17. Savelli G et al. (2001) Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. QJ Nucl Med 45: 27-37
18. 18F-fluoride PET/CT. J Nucl Med 47: 287-297
19. Kattan MW et al. (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766-771
20. D'Amico AV et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974
21. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597
22. Roberts SG et al. (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76: 576-581
23. Freedland SJ et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439
24. Dotan ZA et al. (2005) Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23: 1962-1968
25. Crawford ED et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 419-424
26. Knudson G et al. (1991) Bone scan as a stratification variable in advanced prostate cancer. Cancer 68: 316-320
27. Soloway MS et al. (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202
28. Rigaud J et al. (2002) Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168: 1423-1426
29. Cook GJ and Fogelman I (2001) The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 31: 206-211
30. Vogel CL et al. (1995) Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13: 1123-1128
31. Johns WD et al. (1990) Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan. Clin Nucl Med 15: 485-487
32. Imbriaco M et al. (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index. Clin Cancer Res 4: 1765-1772
33. Sabbatini P et al. (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17: 948-957
34. Noguchi M et al. (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 27: 195-201
35. Yahara J et al. (2003) Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 92: 379-383
36. Hricak H et al. (2007) Imaging prostate cancer: A multidisciplinary perspective. Radiology 243: 28-53
37. Brenner DJ et al. (2007) Computed tomography - an increasing source of radiation exposure. N Engl J Med 357: 2277-2284
38. Sanal SM et al. (1994) Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. J Clin Oncol 12 1415-1421
39. Steinborn MM et al. (1999) Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23: 123-129
40. Traill ZC et al. (1999) Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin Radiol 54: 448-451
41. Bayley A et al. (2001) A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer 92: 303-310
42. Lecouvet FE et al. (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: Diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25: 3281-3287
43. Juweid ME et al. (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354: 496-507
44. Schöder H et al. (2005) CT in PET/CT: Essential features of interpretation. J Nucl Med 46: 1249-1251
45. Bar-Shalom R et al. (2003) Clinical performance of PET/CT in evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 44: 1200-1209
46. Taira AV et al. (2007) -Detection of bone, metastases: Assessment of integrated FDG PET/CT imaging. Radiology 243: 204-211
47. 18F-fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11: 4761-4769
48. Liu IJ et al. (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 7: 108-111
49. Morris MJ et al. (2005) Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11 7454-7461
50. Larson SM et al. (2008) Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol 18: 65-70
51. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 44: 549-555
52. 11C-choline positron-emission/computed tomography in patients with increasing prostate-specific-antigen levels after primary treatment for prostate cancer. BJU Int 100: 786-793.
53. 18F-choline PET/CT for initial staging of advanced prostate cancer. AJR Am J Roentgenol 187: W618-W621
54. NCCN practice guidelines in oncology - prostate cancer 2007 edition. [http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf] (accessed online 30 June 2008)
55. Cooperberg MR et al. (2005) The changing face of prostate cancer. J Clin Oncol 23: 8146-8151
56. Partin AW et al. (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 277: 1445-1451
57. Stephenson AJ et al. (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98: 715-717
58. Abuzallouf S et al. (2004) Baseline staging of newly diagnosed prostate cancer: A summary of the literature. J Urol 171: 2122-2127
59. Leibovici D et al. (2007) Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 15: 198-204
60. Wolff JM et al. (1998) Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 33: 376-381
61. Lorente JA et al. (1999) Serum bone alkaline phosphatase levels enhance the clinical utility of prostate-specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26 625-632
62. 18F-fluoro-[D]-glucose. Radiology 199: 751-756
63. Salminen E et al. (2002) Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 41: 425-429
64. 18F-fluorodeoxyglucose-positron emission tomography. J Urol 169: 1337-1340
65. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36 73-92
66. Heídenreich A et al. Guidelines on prostate cancer. © European Urological Association 2007 [http://www.uroweb.org/fileadmin/ user_upload/Guidelines/07_Prostate_Cancer_2007.pdf] (accessed 30 June 2008)
67. Guidelines for the management of clinically localized prostate cancer: 2007 update. American Urological Association [http://www.auanet.org/ guidelines/main_reports/proscan07/content.pdf] (accessed 30 June 2008)
68. Bill-Axelson A et al. (2005) Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984
69. 111In-capromab pendetide scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 67: 834-840
70. Terris MK et al. (1991) Utilization of bone scans in conjunction with prostate-specific antigen levels in surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 32: 1713-1717
71. Cher ML et al. (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160: 1387-1391
72. Kane CJ et al. (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61: 607-611
73. Stephenson AJ et al. (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25: 2035-2041